Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI,OTC:OPTHD) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held September 14-16, 2026, at the Lotte New York Palace Hotel.

A Company presentation will be available on demand here beginning Friday, September 11, 2026, at 7:00 a.m. ET. Management will be available for one-on-one meetings throughout the conference.

Investors interested in scheduling a meeting with Optimi management should contact their H.C. Wainwright representative, email meetings@hcwco.com, or register for the conference here.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:

Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:

CORE IR
ir@optimi.net


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

OPTI:CC
The Conversation (0)
Optimi Health

Optimi Health

Natural Psychedelic Wellness Alternatives Capitalizing Diverse Revenue Streams

Natural Psychedelic Wellness Alternatives Capitalizing Diverse Revenue Streams Keep Reading...
Appendix 4C Cashflow Statementand Quarterly Activities Report

Appendix 4C Cashflow Statementand Quarterly Activities Report

The Calmer Co. International Limited (ASX: CCO) submits the following Activities Report and Appendix 4C Cash Flow Statement for the three-month period ended 30th September 2026. Highlights Record quarterly revenue of $2.44 million, up 42% on the prior quarter, driven by wholesale and B2B sales... Keep Reading...
Coles Orders Fiji Kava® FZZR™ – First Flavoured Kava Product to Launch in Australia

Coles Orders Fiji Kava® FZZR™ – First Flavoured Kava Product to Launch in Australia

The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, refers to its ASX announcement of 24 June 2026 and is pleased to advise that Coles has placed its initial order... Keep Reading...
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an... Keep Reading...
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...

Interactive Chart

Latest Press Releases

Related News